[Medication of the month. Tazarotene 0.05%-0.1% (Zorac)]

Rev Med Liege. 2003 Nov;58(11):706-8.
[Article in French]

Abstract

Since April 28th, a new topical retinoid is available in Belgium: tazarotene (Zorac) gel (Pierre Fabre). It exists at two concentrations: 0.05% or 0.1%. It is the first receptor-selective topical retinoid. It is indicated in the treatment of plaque-type psoriasis. In the USA, tazarotene is also licensed for use in the treatment of acne and several studies show its efficacy for the treatment of other skin diseases like photodamage and ichthyoses.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Administration, Topical
  • Dermatologic Agents / administration & dosage
  • Dermatologic Agents / therapeutic use*
  • Dose-Response Relationship, Drug
  • Humans
  • Ichthyosis / drug therapy
  • Nicotinic Acids / administration & dosage
  • Nicotinic Acids / therapeutic use*
  • Psoriasis / drug therapy*
  • Sunburn / drug therapy

Substances

  • Dermatologic Agents
  • Nicotinic Acids
  • tazarotene